
Welcome to Myrexis Inc
Welcome to Myrexis, Inc.
Myrexis, Inc. is a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action. The Company has generated a strong pipeline of differentiated product candidates in oncology and autoimmune diseases. Myrexis is focused on maximizing the therapeutic and commercial value of these molecules by developing potential first-in-class and/or best-in-class treatment options for patients with unmet needs.
Our lead product candidates include:
- Hsp90 Inhibitor Program for cancer
- MPC-8640 a Cancer Metabolism Inhibitor
- MPI-485520 an oral anti-interferon for autoimmune diseases
On February 15, 2012 the Company announced that it has retained Stifel Nicolaus Weisel, an investment banking firm, to assist it in evaluating a full range of strategic alternatives available to the Company. The Company continues to actively pursue business development opportunities for each of its programs.
If you are interested in learning more about our development candidates or collaborating with Myrexis, Inc., please contact our Business Development group:
Gradon KnottsVP, Business Development
business.development@myrexis.com
Announcements
Myrexis Appoints New Executive Management Team in Alignment With Strategic Initiatives ![]()
Myrexis Reports Third Quarter Fiscal Year 2012 Results ![]()
Myrexis Adopts Tax Benefits Preservation Rights Plan to Protect Use of Net Operating Losses Replacing Existing Shareholder Rights Plan ![]()
Myrexis Initiates Resource Alignment ![]()
Myrexis Retains Investment Bank to Explore Strategic Alternatives ![]()
